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Identification and Quantification of Diadenosine
Polyphosphate Concentrations in Human Plasma
Joachim Jankowski, Vera Jankowski, Udo Laufer, Markus van der Giet, Lars Henning,
Martin Tepel, Walter Zidek, Hartmut Schlüter
Objective—Diadenosine polyphosphates have been demonstrated to be involved in the control of vascular tone as well as
the growth of vascular smooth muscle cells and hence, possibly, in atherogenesis. In this study we investigated the
question of whether diadenosine polyphosphates are present in human plasma and whether a potential source can be
identified that may release diadenosine polyphosphates into the circulation.
Methods and Results—Plasma diadenosine polyphosphates (ApnA with n3 to 6) were purified to homogeneity by
affinity-, anion exchange-, and reversed phase-chromatography from deproteinized human plasma. Analysis of the
homogeneous fractions with matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) revealed
molecular masses ([MH]) of 757, 837, 917, and 997 d. Comparison of the postsource decay matrix-assisted laser
desorption/ionization mass spectrometry mass spectra of these fractions with those of authentic diadenosine
polyphosphates revealed that these isolated substances were identical to Ap3A, Ap4A, Ap5A, and Ap6A. Enzymatic
analysis showed an interconnection of the phosphate groups with the adenosines in the 5-positions of the ribose
moieties. The mean total plasma diadenosine polyphosphate concentrations (mol/L; mean  SEM) in cubital veins of
normotensive subjects amounted to 0.890.59 for Ap3A, 0.720.72 for Ap4A, 0.330.24 for Ap5A, and 0.180.18 for
Ap6A. Cubital venous plasma diadenosine polyphosphate concentrations from normotensives did not differ significantly
from those in the hypertensive patients studied. There was no significant difference between arterial and venous
diadenosine polyphosphate plasma concentrations in 5 hemodialysis patients, making a significant degradation by
capillary endothelial cells unlikely. Free plasma diadenosine polyphosphate concentrations are considerably lower than
total plasma concentrations because approximately 95% of the plasma diadenosine polyphosphates were bound to
proteins. There were no significant differences in the diadenosine polyphosphate plasma concentrations depending on
the method of blood sampling and anticoagulation, suggesting that platelet aggregation does not artificially contribute
to plasma diadenosine polyphosphate levels in significant amounts.The ApnA (with n3 to 6) total plasma
concentrations in adrenal veins were significantly higher than the plasma concentrations in both infrarenal and
suprarenal vena cava: adrenal veins: Ap3A, 4.051.63; Ap4A, 6.182.08; Ap5A, 0.530.28; Ap6A, 0.590.31;
infrarenal vena cava: Ap3A, 1.250.66; Ap4A, 0.910.54; Ap5A, 0.250.12; Ap6A, 0.110.06; suprarenal vena cava:
Ap3A, 1.400.91; Ap4A, 1.841.20; Ap5A, 0.330.13; Ap6A, 0.110.07 (mol/L; mean  SEM; each P0.05
(concentration of adrenal veins versus infrarenal or suprarenal veins, respectively).
Conclusion—The presence of diadenosine polyphosphates in physiologically relevant concentrations in human plasma was
demonstrated. Because in adrenal venous plasma significantly higher diadenosine polyphosphate concentrations were
measured than in plasma from the infrarenal and suprarenal vena cava, it can be assumed that, beside platelets, the
adrenal medulla may be a source of plasma diadenosine polyphosphates in humans. (Arterioscler Thromb Vasc Biol.
2003;23:1231-1238.)
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In the circulation diadenosine polyphosphates have beenshown to be important extracellular mediators affecting
vascular tone, growth of vascular cells (for review, see
references1,2), and platelet aggregation.3,4 Diadenosine tri-
and tetraphosphate (Ap3A, Ap4A) were the first diadeno-
sine polyphosphates to be identified in human platelets,5,6
followed by diadenosine penta- and hexaphosphate (Ap5A,
Ap6A)7 and diadenosine heptaphosphate (Ap7A).8 In 1999,
diadenosine diphosphate (Ap2A) and Ap3A were shown to
be present in human myocardial tissue.9 Dinucleoside
diphosphates, Ap2A, Ap2G, and Gp2G are described as a
new class of growth-promoting extracellular mediators,
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which are released from granules after activation of
platelets.10
Dinucleoside polyphosphates can be released into the
circulation from activated platelets,5–8,11 from chromaffin
cells of the adrenal glands,12–16 or from synaptic vesicles.17
After their release, local concentrations in the range of 105
mol/L or even higher can be assumed.18 Like ATP, the
dinucleoside polyphosphates may be coreleased with cate-
cholamines on sympathetic nerve stimulation and may thus
significantly modify the cardiovascular actions of the sym-
pathoadrenergic system.12
Diadenosine polyphosphates can act as vasoconstrictors or
vasodilators in rat mesenteric arteries19 and in the vasculature
of the rat kidney.20 Ap5A is the most potent vasoconstricting
diadenosine polyphosphate, followed by Ap6A and Ap4A.
The ionotropic P2X1 receptor is considered the principal
mediator of vasoconstriction.21 The P2X1 receptors cluster on
the adventitial surface of vascular smooth muscle cells
immediately adjacent to sympathetic nerve varicosities.22 The
P2X1 receptor is coexpressed with P2X2, P2X4, and P2X5
receptors in muscle cells of a number of blood vessels,
suggesting that also heteromeric P2X receptors occur.23–25
Not only P2X receptors but also metabotropic P2 years
receptors have been reported to mediate vasoconstriction.26–29
Besides these purinergic receptors, a specific dinucleotide
receptor was described in rat midbrain synaptosomes.30 The
dinucleotide receptor is preferentially stimulated by diaden-
osine polyphosphates and is insensitive to ATP, UTP, aden-
osine, and their respective analogues.30
Beside the vasoactive actions, growth-stimulating effects
of nucleoside polyphosphates have been shown in numerous
blood vessels, involving the subsequent activation of protein
kinase C, Raf-1, and mitogen-activated protein kinase.31,32
Activation of the P2Y2 receptor increases the expression of
c-fos mRNA in cultured aortic smooth muscle cells.33
Dinucleoside polyphosphates also stimulate proliferation in
vascular tissue where Ap4A was shown to be equipotent as
ATP.34 The proliferative effect of the Gp5G and Gp6G is
significantly stronger than ATP in vascular tissues.11
In the present study, an assay for isolation, identification,
and quantification of plasma diadenosine polyphosphates
(ApnA with n3 to 6) was established. Moreover, the present
study was aimed to gain data on the secretion of diadenosine
polyphosphates into plasma to define the sources of plasma
diadenosine polyphosphates in humans. Therefore, plasma
levels in adrenal veins were compared with those in vena cava
to examine whether human adrenal glands release diadeno-
sine polyphosphates.
Materials and Methods
Chemicals
High-performance liquid chromatography water (gradient grade) and
acetonitrile were purchased from Merck (Germany). All other
substances were from Sigma-Aldrich (Germany).
Isolation and Identification of Diadenosine
Polyphosphates in Human Plasma
Peripheral blood (4 mL) was obtained by catheterization of the
cubital vein and was collected in tubes containing K2-EDTA (7.2
mg). Moreover, adrenal venous blood (4 mL) was obtained by
catheterization of adrenal veins, which was performed to further
evaluate primary hyperaldosteronism in 6 hypertensive patients with
clinical and biochemical evidence of that disease and were collected
in tubes containing K2-EDTA (7.2 mg). Samples were also obtained
from inferior vena cava and from cubital veins. All patients had an
adrenal vein catheter because of primary hyperaldosteronism with
unremarkable adrenal computed tomography scan. The clinical and
biochemical characteristics of the patients are given in Table 1. In
none of the patients the diagnosis of an adrenal adenoma was made,
in all 6 patients bilateral hyperplasia was assumed. For comparison,
6 samples from normotensive age- and sex-matched patients (blood
pressure 1194/812 mm Hg) being treated for acute minor illness,
such as back pain or dyspepsia, were collected. In 5 hemodialysis
patients (Table 1) the arteriovenous concentration gradient was
determined using mixed venous and arterial blood, which was taken
from the arteriovenous Cimino fistula. The study was approved by
the local ethical committee.
To test whether intravascular degradation of diadenosine polypho-
sphates by capillary endothelial cells affected diadenosine polypho-
sphate concentrations, the arteriovenous gradient of diadenosine
polyphosphates was determined in 5 patients on regular hemodialysis
treatment. Arterial blood was taken from the Cimino fistulas and
venous blood from the cubital vein.
The blood samples were centrifuged at 2100g for 10 minutes at
4°C for isolation of plasma (step 1). All blood samples were
centrifuged after a standardized interval of 15 minutes after sam-
pling. The plasma was deproteinized with 0.6 mol/L (final concen-
tration) perchloric acid and centrifuged (2100g for 5 minutes at 4°C;
step 2). After adjusting pH to 7.0 with 5 mol/L KOH, the precipitated
proteins and KClO4 were removed by centrifugation (2100g for 5
minutes at 4°C).
To test whether the method of blood sampling and anticoagulation
might artificially affect plasma diadenosine polyphosphate concen-
trations as a result of platelet aggregation, the above method of blood
sampling was compared with best-practice conditions for limiting
platelet activation.35,36 To this purpose, blood (4 mL) of 6 healthy
control subjects was collected from the cubital vein using a 19-G
winged infusion set and tubes containing citrate 0.11 mol/L at a pH
of 8.1. Citrated blood was centrifuged at 120g for 15 minutes to
obtain platelet-rich plasma, which was centrifuged at 300g for 20
minutes at room temperature. The supernatant was used for diaden-
osine polyphosphate determinations.
Determination of the Amount of Protein-Bound
Diadenosine Polyphosphates in Human Plasma
To test the percentage of protein-bound diadenosine polyphosphates,
plasma was isolated as described above and divided into 2 parts. One
part was ultrafiltrated with a centrifuge filter (size exclusion limit: 10
kd; 3400g for 10 minutes at 25°C), and the other was left untreated.
Then, in both portions the diadenosine polyphosphate concentrations
were determined as described below.
TABLE 1. Clinical and Biochemical Characteristics of the
Patients and Control Subjects
Hyperaldosteronism
Patients
(N6)
Hemodialysis
Patients
(N5)
Control
Subjects
(N6)
Age, y 59.610.4 60.412.9 54.511.2
Sex, M/F 3/3 3/2 3/3
Blood pressure, mm Hg 1637/984 1456/794 1194/812
Red blood cells, pl1 4.90.4 3.30.5 5.20.3
White blood cells, nL 7.72.5 8.42.7 6.82.6
Platelets, nL 25375 20472 23468
Values are meanSEM.
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Extraction of Human Plasma for Quantification of
Diadenosine Polyphosphates
After deproteinization diadenosine octaphosphate (5 g) was added
to the sample as internal standard. Triethylammonium acetate
(TEAA) in water was added to the deproteinated plasma to a final
concentration of 40 mmol/L. The mixture was loaded to a prepara-
tive reversed-phase column (step 3, Lichroprep RP-18, 24010 mm,
Merck, Germany; equilibration and sample buffer: 40 mmol/L
TEAA in water; flow rate: 2.5 mL/min). Diadenosine polyphos-
phates were eluted by 30% acetonitrile in water and lyophilized.
Next, the eluate was dissolved in 1 mol/L ammonium acetate at
pH 9.5 and concentrated on a phenyl boronic acid resin, prepared
according to Barnes et al37 (step 4). The substances were eluted from
the phenyl boronic acid resin by 1 mmol/L HCl in water (flow rate:
0.2 mL/min). The eluate from the phenyl boronic acid resin with 1
mol/L TEAA to a final concentration of 40 mmol/L added was
desalted by a reversed-phase high-performance liquid chromatogra-
phy (step 5; Supersphere RP-18 endcapped, 2504 mm, Merck,
Germany; eluent A: 40 mmol/L TEAA in water; eluent B: acetoni-
trile; flow rate: 0.5 mL/min).
The desalted and lyophilized eluate of the phenyl boronic acid
resin was chromatographed by anion-exchange chromatography
(UnoQ-1, 735 mm, Bio-Rad, Hercules, Calif; eluent A: 20 mmol/L
K2HPO4, pH 8; eluent B: 20 mmol/L K2HPO4, pH 8 with 1 mol/L
NaCl; gradient: 0 to 2 minutes, 0% B; 2 to 100 minutes, 0 to 40% B,
100 to 105 minutes, 40 to 100% B, 105 to 116 minute, 100% B; flow
rate: 0.5 mL/min). Fractions were collected according to UV
absorbance at 254 nm (peak fractionation).
To the eluate of the anion-exchange chromatography, 1 mol/L
TEAA was added (final concentration of 40 mmol/L) and were
loaded to an analytic reversed-phase column (Supersphere 100
RP-18 endcapped, 2504 mm, Merck). Nucleoside polyphosphates
were eluted by 20% acetonitrile in water. The isolated diadenosine
polyphosphates were identified by matrix-assisted laser desorption/
ionization mass spectrometry (MALDI-MS), postsource decay
(PSD)-MALDI-MS, as well as enzymatic cleavage experiments.
Moreover, to validate the identification of the diadenosine polypho-
sphates by their retention time to aliquots of the samples, authentic
Ap3A, Ap4A, Ap5A, and Ap6A (each 1 g) were added. For
quantification of diadenosine polyphosphate, peak areas were deter-
mined by an integrator (Merck-Integration). The concentrations of
diadenosine polyphosphates were calculated by using calibration
curves obtained with authentic diadenosine polyphosphates.
Enzymatic Cleavage Experiments
Aliquots of the desalted fractions of anion-exchange chromatography
were incubated with enzymes as follows. The samples were dis-
solved (1) in 20 L 200 mmol/L Tris buffer (pH 8.9) and incubated
with 5-nucleotide hydrolase (3 mU; from Crotalus durissus, EC
3.1.15.1, from Boehringer Mannheim, Germany, purified according
to Sulkowski and Laskowski38 for 9 minutes at 37 °C); (2) in 20 L
200 mmol/L Tris and 20 mmol/L EDTA buffer (pH 7.4) and
incubated with 3-nucleotide hydrolase (1 mU; from calf spleen, EC
3.1.16.1, from Boehringer Mannheim, Germany) 1 hour at 37°C; and
(3) in 20 L 10 mmol/L Tris, 1 mmol/L ZnCl2, and 1 mmol/L MgCl2
buffer (pH 8) and incubated with alkaline phosphatase (1 mU; EC
3.1.3.1, from calf intestinal mucosa, from Boehringer Mannheim,
Germany) for 1 hour at 37°C. The reaction was terminated by an
ultrafiltration with a centrifuge filter (exclusion limit 10 kd).
After filtration of the enzymatic cleavage products, the filtrate,
dissolved in 80 L of eluent A, was subjected to reversed-phase
chromatography (Chromolith SpeedROD, 4.650 mm, Merck, Ger-
many; eluent A: 2 mmol/L tetrabutylammonium hydrogensulfate in
10 mmol/L K2HPO4, pH 6.8; eluent B: 80% acetonitrile in water;
gradient: 0 to 30 minutes, 0 to 40% B; 30 to 33 minutes, 40 to 100%
B; 33 to 36 minutes, 100 % B; flow: 1 mL/min).
Matrix-Assisted Laser Desorption/Ionization Mass
Spectrometry (MALDI-MS)
Aliquots of the desalted fractions of anion-exchange chromatography
were examined by MALDI-MS and PSD-MALDI-MS. A reflectron
type time-of-flight mass spectrometer (Reflex III, Bruker, Germany)
was used according to Hillenkamp and Karas.39 The sample was
mounted on an x, y, and z movable stage allowing irradiation of
selected sample areas. In this study, a nitrogen laser (VSL-337 ND,
Laser Science) with an emission wavelength of 337 nm and 3 NS
pulse duration was used. The laser beam was focused to a diameter
of 50 m at an angle of 45° to the surface of a target. Microscopic
sample observation was possible. Single spectra (10 to 20) were
accumulated for a better signal-to-noise ratio. In MALDI-MS, large
fractions of the desorbed analyte ions undergo PSD during flight in
the field free drift path. Using a reflectron type time-of-flight set-up,
sequence information from PSD fragment ions of precursors pro-
duced by MALDI was obtained.40 Sample preparations for
MALDI-MS and PSD-MALDI-MS experiments were identical. The
concentrations of the substances analyzed were 1 to 10 mol/L in
bidistilled water. Analyte solution (1 L) was mixed with 1 L of
matrix solution (50 mg/mL 3-hydroxy-picolinic acid in water). To
this mixture cation exchange beads (AG 50 W-X12, 200 to 400
mesh, Bio-Rad) equilibrated with NH4 as counter ion were added to
remove Na and K ions. The mixture was gently dried on an inert
metal surface before introduction into the mass spectrometer. The
mass accuracy was in the range of approximately 0.01%.
Synthesis and Chromatography of Diadenosine
Octaphosphate as Internal Standard
Diadenosine octaphosphate was synthesized and chromatographed as
described elsewhere.41 Briefly, Ap8A was synthesized by mixing
adenosine tetraphosphate (50 mmol/L) with 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide (2.5 mol/L), HEPES (2 mol/L),
and magnesium chloride (125 mmol/L). The substances were dis-
solved in water, thoroughly mixed with a vortex mixer, and incu-
bated at 37°C at pH 6.5 for 48 hours. The reaction mixture was
concentrated on a preparative C18 reversed-phase column (LiChro-
prep, 31065 mm, 65 to 40 m, Merck, Germany) using 40 mmol/L
aqueous TEAA in water (eluent A; flow rate: 2 mL/min). After
removing substances not binding to the gel with aqueous 40 mmol/L
TEAA (flow rate: 2 mL/min), nucleosides containing fraction were
eluted with 30% acetonitrile in water (eluent B; flow rate: 2
mL/min). By this procedure, the recovery of Ap8A was about 10% of
the diadenosine octaphosphate used.
The concentrate was displaced on 2 reversed-phase columns
(columns: Supersphere RP-18 endcapped, 3008 mm, Merck, Ger-
many; carrier: 40 mmol/L TEAA in water; displacer: 160 mmol/L
n-butanol; flow 100 L/min). As a result of displacement chroma-
tography anion-exchange chromatography yielded baseline sepa-
rated diadenosine polyphosphates. The identity of the diadenosine
polyphosphates was ascertained using with MALDI-MS as described
above.
Validity of the Assay
Stock solutions of diadenosine polyposphates (100 mol/L) were
prepared in water. Stock solutions were stored at 30°C. Solutions
with various diadenosine polyphosphate concentrations were ob-
tained by dilution of the stock solutions with water. For validation of
the assay, standard diadenosine polyphosphate solutions of different
concentrations were added to plasma directly before thawing. The
precision of the assay for diadenosine polyphosphates was deter-
mined using a plasma sample and authentic diadenosine polyphos-
phate solutions. The intra- (n4) and interassay (n4) variabilities
were assessed and expressed as coefficients of variation (C.V.).
Statistics
Results are presented as meansSEM. Two-sided probability values
less than 0.05 were considered significant. All values reported are
meansSEM
Results
Figure 1 shows the characteristic anion-exchange chromato-
gram of an extract from human plasma after precipitation of
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proteins and affinity chromatography. The peaks labeled in
Figure 1 represents the diadenosine polyphosphates Ap3A,
Ap4A, Ap5A, and Ap6A.
The identity of the diadenosine polyphosphates was con-
firmed by MALDI-MS as well as PSD-MALDI-MS (Table
2). A characteristic PSD-MALDI-MS of Ap5A is given in
Figure 2.
To exclude that the diadenosine polyphosphates found are
isomers with other than 5-5 bonds between the ribose and
the phosphate moieties, the isolated substances were incu-
bated with 3- and 5-nucleotide hydrolase as well as with
alkaline phosphatase. When the fractions containing the
diadenosine polyphosphate (Figure 3A) were treated with
5-nucleotide hydrolase (Crotalus durissus), the UV peak of
the intact diadenosine polyphosphate decreased and UV
peaks of the hydrolysis products AMP, ADP, ATP, and
adenosine tetraphosphate (Ap4) and adenosine pentaphos-
phate (Ap5), respectively, appeared (Figure 3B). Ap5 was
identified by its mass spectrum and by its further sequential
degradation to Ap4, ATP, ADP, and AMP after incubation
with alkaline phosphatase (data not shown). Incubation of the
fractions containing diadenosine polyphosphates with 3-nu-
cleotide hydrolase (Figure 3C) or alkaline phosphatase (Fig-
ure 3D) yielded no cleavage products. Figure 3 shows
representative chromatograms of the enzymatic cleavage
experiments with diadenosine pentaphosphate before (Figure
3A) and after incubation with 5-nucleotide hydrolase (Figure
3B), 3-nucleotide hydrolase (Figure 3C), and alkaline phos-
Figure 3. Chromatograms of the desalted fraction of the anion-
exchange chromatography labeled as Ap5A in Figure 1 (after
anion-exchange and reversed-phase chromatography) before
(Figure 3A) and after (Figure 3B) incubation with 5-nucleotidase,
with 3-nucleotidase (Figure 3C) and with alkaline phosphatase
(Figure 3D). Column: Chromolith SpeedROD, 4.650 mm
(Merck, Germany); eluent A: 2 mmol/L tetrabutylammonium
hydrogensulfate in 10 mmol/L K2HPO4; eluent B: 80% acetoni-
trile in water; gradient: 0 to 30 minutes, 0 to 40% B; 30 to 33
minutes, 40 to 100% B; 33 to 36 minutes, 100% B; flow rate:
0.5 mL/min).
Figure 1. Typical anion-exchange chromatogram of a plasma
extract of adrenal veins (UnoQ-1 735 mm, Bio-Rad, Hercules,
Calif; eluent A: 20 mmol/L K2HPO4, pH 8; eluent B: 20 mmol/L
K2HPO4, pH 8 with 1 mol/L NaCl; gradient: 0 to 2 minutes, 0%
B; 2 to 100 minutes, 0 to 40% B; 100 to 105 minutes, 40 to
100% B; 105 to 116 minutes, 100% B; flow rate: 0.5 mL/min).
TABLE 2. Molecular Masses of Characteristic Fragments From
the PSD-MALDI-MS Spectra of the Desalted Fractions of the
Anion-Exchange Chromatography (Figure 1) Labeled Ap3A,
Ap4A, Ap5A, and Ap6A
Interpretation of the Fragment
Ions Measured
by PSD-MALDI-MS Ap3A Ap4A Ap5A Ap6A
A 136 136 136 136
A-2 H2O 232 232 232 232
A-H2O 250 250 250 250
Ap1 348 348 348 348
Ap2-H2O 409 410 – 410
Ap2 428 427 427 428
Ap3-H2O – 490 490 490
Ap3 508 508 508 508
MAp2 329 – 489 569
M-Ap1 409 489 569 649
MA – 571 – –
MAH2O – – 668 –
M-A-H2O 605 685 765 845
M-A 622 701 781 861
M 757 837 917 997
M indicates protonated parent ion; A, adenine; A, adenosine; p, phosphate
group, eg, Ap3 is ATP.
Figure 2. Positive-ion PSD-MALDI-MS of the fraction labeled as
Ap5A in Figure 1. A, adenine; A, adenosine; M, protonated par-
ent ion; p, phosphate group, for example, Ap4 adenosine tetra-
phosphate). Abscissa: relative mass/charge, m/z, z1; ordinate:
relative intensity, arbitrary units.
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phatase (Figure 3D). The results of the enzymatic cleavage
experiments show that the polyphosphate chain interconnects
the 2 adenosines via phosphoester bonds to the 5-positions of
the riboses.
The mean diadenosine polyphosphate concentrations
(mol/L; meanSEM) of cubital veins of normotensive
patients amounted to 0.890.59 for Ap3A, 0.720.72 for
Ap4A, 0.330.24 for Ap5A, and 0.180.18 for Ap6A. There
was no significant difference between cubital venous diaden-
osine polyphosphate concentrations in the patients with pri-
mary hyperaldosteronism and in normotensive subjects (Ta-
ble 3). Furthermore, Table 3 shows that there were no
significant differences between central and peripheral venous
diadenosine polyphosphate plasma concentrations. To test
whether the capillary endothelium significantly contributes to
intravascular degradation of diadenosine polyphosphates, ar-
terial and venous plasma diadenosine polyphosphate concen-
trations were compared in 5 hemodialysis patients. The
measurements revealed no significant arteriovenous differ-
ence in any of the diadenosine polyphosphate concentrations
(Table 3).
In a further series of experiments, in 6 healthy probands the
influence of blood sampling on plasma diadenosine polypho-
sphate concentrations was examined, comparing the above
sampling method with best practice conditions. There were
no significant differences in the diadenosine polyphosphate
plasma concentrations with either sampling method
(0.510.09 versus 0.590.26 Ap3A, 0.380.23 versus
0.320.12 for Ap4A, 0.350.27 versus 0.420.09 for Ap5A,
and 0.290.23 versus 0.250.09 for Ap6A (mol/L);
P0.05; n6, each EDTA versus citrate).
The concentrations of Ap3A, Ap4A, Ap5A, and Ap6A in the
plasma of infrarenal vena cava, adrenal veins, and the
suprarenal vena cava are given in Table 3. All patients had an
adrenal vein catheter because of primary hyperaldosteronism
with unremarkable adrenal computed tomography scan. The
clinical and biochemical characteristics of the patients are
given in Table 1. Diagnosis of an adrenal adenoma was made
in none of the patients, and in all 6 patients bilateral
hyperplasia was assumed.
Furthermore, there was no significant difference between
cubital venous diadenosine polyphosphate concentrations in
the patients with primary hyperaldosteronism and in normo-
tensive subjects (Table 3).
Filtration experiments of human plasma using a 10-kd
cut-off filtration membrane revealed that 5.74.5% of the
diadenosine polyphosphates isolated from human plasma
were not protein bound, with no significant differences
depending on the number of phosphate groups.
The plasma concentrations of Ap3A, Ap4A, Ap5A, and
Ap6A in infrarenal vena cava, adrenal veins, and suprarenal
vena cava are given in Table 3. The concentrations of left and
right adrenal veins were determined separately. In the figure,
mean values of left and right adrenal veins are presented.
To test whether the capillary endothelium significantly
contributes to intravascular degradation of diadenosine
polyphosphates, arterial and venous plasma diadenosine
polyphosphate concentrations were compared in 5 hemodial-
ysis patients. The measurements revealed no significant
arteriovenous difference in any of the diadenosine polypho-
sphate concentrations (Table 3).
The absolute recovery of diadenosine-5-5-octaphosphate,
5 g of which were added as internal standard, was found to
be 43.318.6%. The calibration graphs showed good linear-
ity for concentrations of the diadenosine polyphosphates
(Ap3A, Ap4A, Ap5A, Ap6A) ranging from 0.05 to 15 mol/L
(r0.999). The peak area ratios of the diadenosine polypho-
sphates were linear in the concentration ranges investigated.
Based on a signal-to-noise ratio of 3, the detection limit for
the diadenosine polyphosphates was 16 nmol/L. The preci-
sion of the assay for diadenosine polyphosphates was deter-
mined using a plasma sample and authentic diadenosine
polyphosphates.
To evaluate the quantification of diadenosine polyphos-
phates in human plasma, the intra- (n4) and interassay
(n4) variabilities were assessed. The intra-assay variability
for a human plasma sample and standard solutions, assessed
on 4 consecutive working days, was 8.2%. The interassay
coefficient of variation for a plasma sample and a standard
solution, assessed on 4 consecutive working days, was
11.1%.
Discussion
Quantification of diadenosine polyphosphates from human
plasma requires several sample preparation steps. First, the
large amounts of proteins and peptides have to be removed.
These substances were denatured by perchloric acid and
removed by centrifugation. Second, the large number of small
hydrophobic and hydrophilic substances has to be separated.
Third, carbohydrates have to be removed from the sample
before affinity chromatography because of the ability of
TABLE 3. Plasma Diadenosine Polyphosphate Concentrations Obtained From Patients With Primary Hyperaldosteronism Subjected to
Adrenal Vein Catheter, From Normotensive Patients, and From Arterial and Venous Plasma of Hemodialysis Patients
Hyperaldosteronism Patients Normotensive Patients Hemodialysis Patients
Significance/Adrenal Veins
vs Infrarenal and
Suprarenal Vena Cava
Infrarenal Vena
Cava Primary
Adrenal Veins
Primary
Suprarenal Vena
Cava Primary
Cubital Vein
Primary
Cubital
Vein
Arterial
Plasma
Venous
Plasma
Ap3A 1.250.66 4.051.63 1.400.91 0.830.27 0.890.59 0.850.32 0.750.30 P0.05
Ap4A 0.910.54 6.182.08 1.841.20 0.560.24 0.720.72 0.540.31 0.710.20 P0.05
Ap5A 0.250.12 0.530.28 0.330.13 0.530.19 0.330.24 0.240.09 0.310.15 P0.05
Ap6A 0.110.06 0.590.31 0.110.07 0.290.19 0.180.18 0.100.10 0.140.11 P0.05
Values are meanSEM in mol/L.
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carbohydrates to bind to the affinity gel. These aims were
achieved by reversed-phase chromatography.
Next, a highly selective concentration step with a boronate
derivative of a cation exchange gel was used, which selec-
tively retains nucleoside polyphosphates containing 2 or more
sets of 1,2 cis-diol groups. Whereas mononucleoside
polyphosphates like ATP with less than 2 cis-diol groups do
not bind in ammonium acetate at buffer concentrations of 1
mol/L to the boronate gel because of charge repulsions
between the negative phosphate groups and the carboxyl
groups of the cation-exchange gel, the boryl ester formation
of the 2 cis-diol groups of diadenosine polyphosphates is
sufficient to overcome charge repulsion.37 The eluate from
the boronate gel contained salts that prevented diadenosine
polyphosphates from binding to the anion exchanger. There-
fore, the eluate was desalted by concentration on a reversed-
phase gel. For quantification of the diadenosine polyphos-
phates the plasma extract from the reversed-phase
chromatography was subjected to anion-exchange
chromatography.
The diadenosine polyphosphate concentrations in human
plasma were found to be in the mol range. From the
concentration–response curves published, it appears that cir-
culating diadenosine polyphosphates affect vascular tone.
Moreover, in concentrations 108 mol/L diadenosine
polyphosphates have a growth-stimulating effect on vascular
smooth muscle cells.10,42,43 Given the EC50 value for Ap5A in
the 108 mol/L range, the plasma levels reported here seem
surprisingly high. Because it is highly unlikely that the
plasma diadenosine phosphate concentrations exceed the
EC50 by 2 orders of magnitude, the question arises whether or
not a part of the circulating diadenosine polyphosphates
exists in a bound form. Indeed, the results show that a
considerable portion of plasma diadenosine polyphosphates is
protein bound, as they are retained by a 10-kd filter. There-
fore, it may be assumed that only a small portion of total
plasma diadenosine polyphosphates directly affects vascular
tone.
The findings show that diadenosine polyphosphate concen-
trations vary within the venous system and depend on the
number of phosphate groups contained in the molecule. The
adrenal venous diadenosine polyphosphate concentrations
higher than those in other veins leave 2 alternative explana-
tions: either diadenosine polyphosphates are produced by the
adrenal medulla or adrenal vascular endothelium is less
effective in degrading diadenosine polyphosphates by its
ectonucleases than other endothelial cells. Between both
hypotheses, a decision can be made on the basis of arterial
diadenosine polyphosphate concentrations. The measure-
ments revealed that there is no significant gradient between
nonadrenal venous and arterial diadenosine polyphosphate
concentrations. This finding implies that the ectonucleases
located on vascular endothelial cells do not degrade sufficient
amounts of diadenosine polyphosphates to lower venous
diadenosine polyphosphate concentrations significantly.
Therefore, the increased adrenal venous plasma diadenosine
polyphosphate concentrations compared with nonadrenal ve-
nous plasma cannot be due to a decreased endothelial
degradation restricted to adrenal vascular endothelium.
The concentrations of the various diadenosine polyphos-
phates differ from each other. Obviously, those diadenosine
polyphosphates with a higher number of phosphate groups
show lower concentrations than those with a lower number of
phosphates. This pattern may either be the result of an
increased degradation of diadenosine polyphosphates by cir-
culating and endothelial enzymes or by a decreased rate of
synthesis with increasing number of phosphate groups. Al-
though this question cannot be solved on the basis of the
present data, findings reported in the literature may give an
answer: concerning platelets, several studies revealed that the
diadenosine polyphosphate contents decreased with an in-
creasing number of phosphate groups.42,44 Because the in-
traplatelet diadenosine polyphosphates are not accessible by
the extracellular degrading enzymes, it appears more likely
that the synthetic pathway is less effective with increasing
number of phosphate moieties to be incorporated.
In earlier studies, platelet diadenosine polyphosphates had
been quantified referring the platelets content to the pertinent
whole blood volume. In the platelets contained in 1 L of
whole blood, the following amounts of diadenosine polypho-
sphates were found44: Ap3A, 192.514.7 nmol; Ap4A,
223.816.8 nmol; Ap5A, 100.27.9 nmol; Ap6A, 32.01.9
nmol (mean  SEM). Conceivably, even if 100% of the
platelet diadenosine polyphosphates are assumed to be re-
leased and hence to be distributed within the pertinent
volume, the resulting plasma concentrations would be far less
than those reported here. Therefore, a significant artificial
contribution to plasma diadenosine polyphosphates by plate-
let aggregation appears to be unlikely. This conclusion is
further supported by the fact that the method of blood
sampling and anticoagulation does not significantly affect
plasma diadenosine polyphosphate concentrations when best-
practice conditions are compared with those initially applied.
Therefore, human plasma diadenosine polyphosphates can-
not solely stem from platelets. Thus, we tested the hypothesis
that diadenosine polyphosphates in human plasma are, at least
partially, derived from the adrenal glands. Adrenal venous
plasma diadenosine polyphosphate concentrations are signif-
icantly higher than those in the vena cava, both infrarenally
and suprarenally (Table 3). This result suggests that human
adrenal glands release Ap3A, Ap4A, Ap5A, and Ap6A.
These results are in accordance with results from animal
experiments, which showed that the adrenal medulla contains
diadenosine polyphosphates.16 They are released from per-
fused bovine adrenal glands and also from isolated chromaf-
fin cells activated with carbachol. The ratio of the released
diadenosine polyphosphates to released ATP and catechol-
amines is in the same order as that found in isolated
chromaffin granules.14 With regard to these results, it can be
inferred that diadenosine polyphosphates are also released by
the chromaffin granules of human adrenal glands.
To what extent may these findings be relevant for human
physiology and pathophysiology? If the adrenal medulla
secretes not only adrenaline and noradrenaline into the
circulation but also diadenosine polyphosphates, this seems to
be of minor clinical significance because substitution of
adrenal steroids is generally sufficient to restore well-being
and normal hemodynamics after bilateral adrenalectomy.
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Severe adrenal insufficiency, eg, Addison’s disease, which is
caused by several diseases, may be another example that the
systemic actions of diadenosine polyphosphate are limited.
The clinical picture after destruction of the medulla and
cortex, which occurs after adrenal tuberculosis, does not
show significant differences to the clinical picture after
destruction of the cortex alone, which occurs after autoim-
mune adrenalitis. However, the role of adrenal medulla in
vascular and metabolic regulation has not been ultimately
defined, and a potential role of either catecholamines or other
secretory products, such as diadenosine polyphosphates, has
not yet been examined in detail.
Furthermore, over the last decades it has been repeatedly
documented that plasma catecholamines are elevated in essential
hypertensive patients. Noteworthy, increased adrenaline levels
have been consistently reported. From this finding, the sympa-
thetic nervous system can be excluded as the sole source of
increased plasma catecholamines because chromaffine tissue but
not the sympathetic nervous system is capable of synthesizing
adrenaline. Because diadenosine polyphosphates and catechol-
amines are generally coreleased by adrenal or sympathetic
nervous tissue, diadenosine polyphosphates may also be secreted
in increased amounts in essential hypertension. Indeed, there is
1 report showing increased platelet diadenosine polyphosphate
contents in essential hypertension.45 Therefore, the present
findings suggest that an increased diadenosine polyphosphate
secretion by the adrenal medulla may be 1 potential mechanism
underlying increased platelet diadenosine polyphosphates in
essential hypertension.45
Plasma diadenosine polyphosphate levels in essential hy-
pertension have not been determined in this study because the
patients studied had all exhibited a primary hyperaldosteron-
ism. In these patients, peripheral venous plasma diadenosine
polyphosphate concentrations were similar to those seen in
normotensive controls.
In summary, plasma concentrations of diadenosine
polyphosphates in the range of 106 mol/L are compatible
with systemic effects of these agents. By this finding, our
view on diadenosine polyphosphates as hormones may be
modified and extended.
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